Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1975 1
1981 1
1999 1
2001 1
2002 1
2004 2
2005 2
2006 1
2007 3
2008 5
2009 6
2010 6
2011 12
2012 12
2013 10
2014 8
2015 13
2016 19
2017 23
2018 16
2019 10
2020 15
2021 24
2022 17
2023 18
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

208 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Neural glioblastoma"
Page 1
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.
Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, Khan SA, Loibl S, Morris EA, Perez A, Regan MM, Spears PA, Sudheendra PK, Symmans WF, Yung RL, Harvey BE, Hershman DL. Korde LA, et al. J Clin Oncol. 2021 May 1;39(13):1485-1505. doi: 10.1200/JCO.20.03399. Epub 2021 Jan 28. J Clin Oncol. 2021. PMID: 33507815 Free PMC article.
Although tumor histology, grade, stage, and estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) expression should routinely be used to guide clinical decisions, there is insufficient evidence to support the use of other markers or genomic profiles. …
Although tumor histology, grade, stage, and estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) expression should ro …
Glioblastoma remodelling of human neural circuits decreases survival.
Krishna S, Choudhury A, Keough MB, Seo K, Ni L, Kakaizada S, Lee A, Aabedi A, Popova G, Lipkin B, Cao C, Nava Gonzales C, Sudharshan R, Egladyous A, Almeida N, Zhang Y, Molinaro AM, Venkatesh HS, Daniel AGS, Shamardani K, Hyer J, Chang EF, Findlay A, Phillips JJ, Nagarajan S, Raleigh DR, Brang D, Monje M, Hervey-Jumper SL. Krishna S, et al. Nature. 2023 May;617(7961):599-607. doi: 10.1038/s41586-023-06036-1. Epub 2023 May 3. Nature. 2023. PMID: 37138086 Free PMC article.
Here we sought to determine how glioma-induced neuronal changes influence neural circuits underlying cognition and whether these interactions influence patient survival. ...Pharmacological inhibition of thrombospondin-1 using the FDA-approved drug gabapentin decreases g …
Here we sought to determine how glioma-induced neuronal changes influence neural circuits underlying cognition and whether these inte …
An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment.
Verdugo E, Puerto I, Medina MÁ. Verdugo E, et al. Cancer Commun (Lond). 2022 Nov;42(11):1083-1111. doi: 10.1002/cac2.12361. Epub 2022 Sep 21. Cancer Commun (Lond). 2022. PMID: 36129048 Free PMC article. Review.
Glioblastoma multiforme (GBM) is the most aggressive and common malignant primary brain tumor. ...Several molecular parameters have been used to achieve an accurate and personalized characterization of glioblastoma in patients, including epigenetic, genetic, transcr …
Glioblastoma multiforme (GBM) is the most aggressive and common malignant primary brain tumor. ...Several molecular parameters have b …
Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.
Fares J, Ahmed AU, Ulasov IV, Sonabend AM, Miska J, Lee-Chang C, Balyasnikova IV, Chandler JP, Portnow J, Tate MC, Kumthekar P, Lukas RV, Grimm SA, Adams AK, Hébert CD, Strong TV, Amidei C, Arrieta VA, Zannikou M, Horbinski C, Zhang H, Burdett KB, Curiel DT, Sachdev S, Aboody KS, Stupp R, Lesniak MS. Fares J, et al. Lancet Oncol. 2021 Aug;22(8):1103-1114. doi: 10.1016/S1470-2045(21)00245-X. Epub 2021 Jun 29. Lancet Oncol. 2021. PMID: 34214495 Free PMC article. Clinical Trial.
Recruitment is complete and the trial is finished. The trial is registered with ClinicalTrials.gov, NCT03072134. ...Our immunological and histopathological findings support continued investigation of NSC-CRAd-S-pk7 in a phase 2/3 clinical trial. FUNDIN …
Recruitment is complete and the trial is finished. The trial is registered with ClinicalTrials.gov, NCT03072134. ...Our immuno …
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
Shepherd JH, Ballman K, Polley MC, Campbell JD, Fan C, Selitsky S, Fernandez-Martinez A, Parker JS, Hoadley KA, Hu Z, Li Y, Soloway MG, Spears PA, Singh B, Tolaney SM, Somlo G, Port ER, Ma C, Kuzma C, Mamounas E, Golshan M, Bellon JR, Collyar D, Hahn OM, Hudis CA, Winer EP, Partridge A, Hyslop T, Carey LA, Perou CM, Sikov WM. Shepherd JH, et al. J Clin Oncol. 2022 Apr 20;40(12):1323-1334. doi: 10.1200/JCO.21.01506. Epub 2022 Jan 19. J Clin Oncol. 2022. PMID: 35044810 Free PMC article. Clinical Trial.
PURPOSE: CALGB 40603 (NCT00861705), a 2 2 randomized phase II trial, demonstrated that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by doxorubicin and cyclophosphamide significantly increased the pathologic complete response (pCR) rate in sta …
PURPOSE: CALGB 40603 (NCT00861705), a 2 2 randomized phase II trial, demonstrated that adding carboplatin or bevacizumab to we …
Engineered cells as glioblastoma therapeutics.
Ramanathan A, Lorimer IAJ. Ramanathan A, et al. Cancer Gene Ther. 2022 Feb;29(2):156-166. doi: 10.1038/s41417-021-00320-w. Epub 2021 Mar 22. Cancer Gene Ther. 2022. PMID: 33753869 Free PMC article. Review.
In addition to small molecule, antibody, and engineered virus approaches, engineered cells are also being explored as glioblastoma therapeutics. This includes CAR-T cells, CAR-NK cells, as well as engineered neural stem cells and mesenchymal stem cells. Here we revi …
In addition to small molecule, antibody, and engineered virus approaches, engineered cells are also being explored as glioblastoma th …
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey LA, Gelmon K, Hortobagyi GN, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Feng W, Winer E. Curigliano G, et al. Ann Oncol. 2022 Mar;33(3):321-329. doi: 10.1016/j.annonc.2021.12.005. Epub 2021 Dec 23. Ann Oncol. 2022. PMID: 34954044 Free article. Clinical Trial.
We report efficacy and safety outcomes, including the final OS and safety outcomes from follow-up in HER2CLIMB. PATIENTS AND METHODS: HER2CLIMB is a randomized, double-blind, placebo-controlled trial in patients with locally advanced or metastatic HER2+ breast cance …
We report efficacy and safety outcomes, including the final OS and safety outcomes from follow-up in HER2CLIMB. PATIENTS AND METHODS: HER2CL …
Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.
Gholamin S, Mitra SS, Feroze AH, Liu J, Kahn SA, Zhang M, Esparza R, Richard C, Ramaswamy V, Remke M, Volkmer AK, Willingham S, Ponnuswami A, McCarty A, Lovelace P, Storm TA, Schubert S, Hutter G, Narayanan C, Chu P, Raabe EH, Harsh G 4th, Taylor MD, Monje M, Cho YJ, Majeti R, Volkmer JP, Fisher PG, Grant G, Steinberg GK, Vogel H, Edwards M, Weissman IL, Cheshier SH. Gholamin S, et al. Sci Transl Med. 2017 Mar 15;9(381):eaaf2968. doi: 10.1126/scitranslmed.aaf2968. Sci Transl Med. 2017. PMID: 28298418 Free article.
We demonstrate the effect of a humanized anti-CD47 antibody, Hu5F9-G4, on five aggressive and etiologically distinct pediatric brain tumors: group 3 medulloblastoma (primary and metastatic), atypical teratoid rhabdoid tumor, primitive neuroectodermal tumor, pediatric glioblast …
We demonstrate the effect of a humanized anti-CD47 antibody, Hu5F9-G4, on five aggressive and etiologically distinct pediatric brain tumors: …
Gene Delivery in Neuro-Oncology.
Dixit K, Kumthekar P. Dixit K, et al. Curr Oncol Rep. 2017 Sep 2;19(11):69. doi: 10.1007/s11912-017-0628-z. Curr Oncol Rep. 2017. PMID: 28866732 Review.
PURPOSE OF REVIEW: Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults with a dismal prognosis despite aggressive multimodal management thus novel treatments are urgently needed. ...Gene therapy may be a promising treatment strategy in …
PURPOSE OF REVIEW: Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults with a dismal prognosis d …
Potential effects of nicotine on glioblastoma and chemoradiotherapy: a review.
McConnell DD, Carr SB, Litofsky NS. McConnell DD, et al. Expert Rev Neurother. 2019 Jun;19(6):545-555. doi: 10.1080/14737175.2019.1617701. Epub 2019 May 17. Expert Rev Neurother. 2019. PMID: 31092064 Review.
Use of tobacco products following diagnosis and during the period of treatment for non-neural tumors detrimentally affects treatment and prognosis. Approximately, 16-28% of patients with glioblastoma continue to smoke after diagnosis and during treatment. ...English …
Use of tobacco products following diagnosis and during the period of treatment for non-neural tumors detrimentally affects treatment …
208 results